The global biopharmaceutical industry faces ever-increasing business hazards associated with research costs, troublesome patenting (changing standards, vague definitions, and else), significant competition, and more. The main focus area of strategic-thinking biotechnology players is to allocate resources (time, cost) more wisely to reduce those risks and, naturally, increase revenue. Artificial intelligence…